Transformative Technologies for Early Cancer Detection

NavDx Liquid Biopsy

Unique Solutions for Truly Personalized Medicine

Innovative Diagnostic Solutions for Patients and Physicians

Improving patient outcomes through early cancer detection
Naveris develops highly sensitive blood tests, liquid biopsies, that identify viral cancers significantly earlier than is possible with scans or traditional biopsies. Naveris’ lead product, NavDx®, is a liquid biopsy that uses proprietary technology to enable ultrasensitive surveillance of HPV-related cancer.
Learn More About NavDx
Our Core Technology
Our mission at Naveris is to deliver disruptive technology with the potential to transform cancer detection and improve patient outcomes.

Highly Sensitive Blood Tests

Early cancer diagnosis in the general asymptomatic population.

Transform Cancer Detection

Real-time monitoring of response in patients undergoing treatment.

Improve Patient Outcomes

Detection of cancer recurrence in patients in remission.

Publications

Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer (Journal of Clinical Oncology, 2020)

Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer (Clinical Cancer Research 2019)

 

 

Contact
Follow us on: